<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048983</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0345</org_study_id>
    <secondary_id>R01 026582-26</secondary_id>
    <secondary_id>NCI-2012-01256</secondary_id>
    <nct_id>NCT01048983</nct_id>
  </id_info>
  <brief_title>Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and&#xD;
      minocycline when given alone or in combination to learn which is better for controlling&#xD;
      symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      It is not known which study drug or combination of study drugs is better at reducing side&#xD;
      effects patients may experience during chemoradiation therapy. For this reason, researchers&#xD;
      have chosen 4 study drugs that may help to reduce side effects. The study drugs will be&#xD;
      tested alone and in combination with each other.&#xD;
&#xD;
      Armodafinil is designed to prevent excessive sleepiness.&#xD;
&#xD;
      Bupropion is an antidepressant with anti-inflammatory properties that may help reduce&#xD;
      multiple symptoms.&#xD;
&#xD;
      Curcumin is the active ingredient in the spice, turmeric. It may interfere with the&#xD;
      production of cytokines (which cause inflammation), which may reduce multiple symptoms.&#xD;
&#xD;
      Minocycline is an antibiotic. Minocycline has been shown to interrupt cytokine production,&#xD;
      which may help to reduce multiple symptoms.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you agree to take part in this study, you will be randomly assigned (as in the roll of&#xD;
      dice) to join 1 of 16 groups. You may be assigned to receive no study drugs, 1 study drug, or&#xD;
      a combination of 2, 3, or all 4 of the study drugs.&#xD;
&#xD;
      During this study, you may receive 1 or more placebos. A placebo looks like the study drug(s)&#xD;
      but has no active ingredients. There is a chance that you will be in a group that does not&#xD;
      receive any study drugs at all. However, all patients are under standard care by their&#xD;
      treating doctors.&#xD;
&#xD;
      Neither you nor the study staff you will see in the clinic will know if you are receiving the&#xD;
      study drugs and/or the placebo(s). However, if needed for your safety, the study staff will&#xD;
      be able to find out which study drug you are receiving.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will take the study drugs/placebos every day for 10 weeks. You will take either single or&#xD;
      combined study drug(s) or placebos by mouth everyday as instructed by the study doctor.&#xD;
&#xD;
      You will be given pamphlets with more information about how to take the study drugs/placebos.&#xD;
&#xD;
      You will be given a daily diary to write down when you take the study drugs/placebo. You&#xD;
      should bring your study drug/placebo blister packs/sticks to the clinic to every study visit.&#xD;
      You should also bring your diary to every visit.&#xD;
&#xD;
      Completing the Symptom Questionnaire:&#xD;
&#xD;
      Throughout the study, you will be asked to complete the symptom questionnaire. You will be&#xD;
      asked about symptoms from therapy you may be experiencing and how they may be interfering&#xD;
      with your daily activities. The study staff will either meet you during your regular clinic&#xD;
      visit or call you at your home at a time that is convenient for you. In the clinic, you will&#xD;
      complete the questionnaire by paper and pen, or by entering your answers into an electronic&#xD;
      tablet computer. On the phone, study staff will ask you the questions and record your answers&#xD;
      on paper or enter them into a computer. The symptom questionnaire will take up to 5 minutes&#xD;
      to complete.&#xD;
&#xD;
        -  During Weeks 1-10, you will complete the symptom questionnaire 2 times a week.&#xD;
&#xD;
        -  During Weeks 11-16, you will complete the symptom questionnaire 1 time a week.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Before you begin chemoradiation:&#xD;
&#xD;
        -  You will complete 4 questionnaires about pain and other symptoms, your mood, and your&#xD;
           quality of life. Completing all 4 of the questionnaires will take about 15 minutes.&#xD;
&#xD;
        -  You will have a blood coagulation test, called a PT-INR, to make sure your blood clots&#xD;
           normally.&#xD;
&#xD;
        -  If you are a woman who is able to become pregnant, you will have a urine pregnancy test.&#xD;
           The study staff will give you the pregnancy test kit at your scheduled visit, and will&#xD;
           review and record the results of the test before your study prescriptions are filled by&#xD;
           the pharmacy.&#xD;
&#xD;
      After 4 weeks of chemoradiation:&#xD;
&#xD;
        -  You will complete 1 questionnaire about your quality of life. This questionnaire will&#xD;
           take about 2-3 minutes to complete.&#xD;
&#xD;
        -  You will have a blood coagulation test, called a PT-INR, to make sure your blood clots&#xD;
           normally.&#xD;
&#xD;
      During the last week of chemoradiation (about Week 7):&#xD;
&#xD;
      -You will complete 3 questionnaires about your symptoms, mood, and quality of life. These&#xD;
      questionnaires will take about 10 minutes total to complete.&#xD;
&#xD;
      After about Week 7, the study staff will call you 2 times a week to check on you until week&#xD;
      10. This phone call should last only a few minutes. If you have experienced several side&#xD;
      effects from chemoradiation, this phone call make take longer.&#xD;
&#xD;
      About Week 12 (at a routine clinical visit):&#xD;
&#xD;
        -  You will complete 3 questionnaires about your symptoms, mood, and quality of life.&#xD;
&#xD;
        -  If you were smoking at the beginning of the study, you will complete a questionnaire&#xD;
           that asks if you stopped smoking any time during the study. This will take a few&#xD;
           minutes.&#xD;
&#xD;
        -  You will have a blood coagulation test, called a PT-INR, to make sure your blood clots&#xD;
           normally.&#xD;
&#xD;
        -  You will be asked to complete another questionnaire that asks about your satisfaction&#xD;
           with the study drug(s). This will take a few minutes.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be on study for about 16 weeks. You will take the study drug(s) for 10 weeks and&#xD;
      complete the symptom survey until 16 weeks. You will be taken off study if you experience&#xD;
      intolerable side effects.&#xD;
&#xD;
      This is an investigational study. Armodafinil is FDA approved and commercially available for&#xD;
      the treatment of excessive sleepiness. Bupropion is FDA approved and commercially available&#xD;
      for the treatment of depression. Minocycline is FDA approved and commercially available for&#xD;
      the treatment of bacterial infection. Curcumin is not FDA approved. At this time, curcumin is&#xD;
      only being used in research. The different possible combinations of these drugs being used in&#xD;
      this study is investigational.&#xD;
&#xD;
      Up to 32 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No accrual.&#xD;
  </why_stopped>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined AUC for Selected Symptoms</measure>
    <time_frame>10-weeks (+/- 4 days)</time_frame>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Questionnaires and Phone Calls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Armodafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil + Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline + Buproprion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Armodafinil + Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Armodafinil + Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Minocycline + Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin + Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.</description>
    <arm_group_label>Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Armodafinil Only</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline + Bupropion</arm_group_label>
    <other_name>Nuvigil</other_name>
    <other_name>Modafinil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Initial Dose 100 mg two times a day (200 mg) for 10 weeks.</description>
    <arm_group_label>Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Bupropion Only</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Minocycline + Buproprion</arm_group_label>
    <other_name>Wellbutrin</other_name>
    <other_name>Wellbutrin SR</other_name>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Initial Dose 100 mg two times a day (200 mg) for 10 weeks.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Minocycline + Buproprion</arm_group_label>
    <arm_group_label>Minocycline Only</arm_group_label>
    <other_name>Dynacin</other_name>
    <other_name>Minocin</other_name>
    <other_name>Minocin PAC</other_name>
    <other_name>Myrac</other_name>
    <other_name>Solodyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.</description>
    <arm_group_label>Curcumin + Armodafinil</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone Questionnaire</intervention_name>
    <description>Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.</description>
    <arm_group_label>Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Armodafinil Only</arm_group_label>
    <arm_group_label>Bupropion Only</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Armodafinil + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Bupropion</arm_group_label>
    <arm_group_label>Curcumin + Minocycline</arm_group_label>
    <arm_group_label>Curcumin + Minocycline + Bupropion</arm_group_label>
    <arm_group_label>Curcumin Only</arm_group_label>
    <arm_group_label>Minocycline + Buproprion</arm_group_label>
    <arm_group_label>Minocycline Only</arm_group_label>
    <arm_group_label>Questionnaires and Phone Calls</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a pathologically proven diagnosis of unresectable Non-small-cell lung&#xD;
             carcinoma (NSCLC) and consented to concurrent chemoradiation therapy in MD Anderson&#xD;
             Cancer Center (MDACC).&#xD;
&#xD;
          2. Patients &gt;= 18 years old and &lt;= 65 years old&#xD;
&#xD;
          3. Patients who will receive chemoradiation with platinum/taxane based chemo and with a&#xD;
             total radiation dose of &gt; or = 50 Gy, per treating physician's assessment&#xD;
&#xD;
          4. Patients who speak English only (due to the novel research and its complexity, we are&#xD;
             only accruing English speaking patients to the protocol)&#xD;
&#xD;
          5. Patients must agree to discontinue any current herbal supplement use, and refrain from&#xD;
             taking any herbal supplement while on protocol&#xD;
&#xD;
          6. Patients must be willing and able to review, understand, and provide written consent&#xD;
             before starting therapy&#xD;
&#xD;
          7. Patients already taking any of this trial's symptom treatment medications (including&#xD;
             modafinil) must be willing to stop taking the medication/s for a washout period of 30&#xD;
             days before they are randomized to a symptom treatment arm and begin the symptom trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are taking medications or have conditions that potentially preclude use&#xD;
             of any study medications or interventions as determined by the treating physician&#xD;
&#xD;
          2. Patients taking CHANTIX (smoking cessation medication)&#xD;
&#xD;
          3. Patients who are enrolled in other symptom management or treatment clinical trials&#xD;
&#xD;
          4. Bile duct obstruction or cholelithiasis&#xD;
&#xD;
          5. History of clinically significant cutaneous drug reaction, or a history of clinically&#xD;
             significant hypersensitivity reaction, including multiple allergies or drug reaction&#xD;
&#xD;
          6. Pre-existing psychosis or bipolar disorder&#xD;
&#xD;
          7. Pre-existing renal impairment: The screening cut off for serum creatinine &gt;1.5mg/dl&#xD;
             will be done by the oncologist to qualify for CXRT.&#xD;
&#xD;
          8. Pre-existing hepatic impairment: The screening for total bilirubin &gt;25.7 Âµmol/L (1.5&#xD;
             mg/dL) will be done by the oncologist to qualify for chemoradiation treatment (CXRT).&#xD;
             The screening for 2 times the upper limit of normal Hepatotoxicity (Aspartate&#xD;
             aminotransferase (AST), Alkaline phosphatase (ALP) and Alanine aminotransferase (ALT)&#xD;
             will be done by the oncologist to qualify for CXRT.&#xD;
&#xD;
          9. Pre-existing Tourette's syndrome&#xD;
&#xD;
         10. Seizure disorder&#xD;
&#xD;
         11. Anorexia/bulimia in past two months&#xD;
&#xD;
         12. Use of monoamine oxidase (MAO) inhibitors within 14 days&#xD;
&#xD;
         13. Patients undergoing abrupt discontinuation of ethanol or sedatives (including&#xD;
             benzodiazepines)&#xD;
&#xD;
         14. Patients receiving other dosage forms of bupropion if they do not agree to undergo a&#xD;
             washout period&#xD;
&#xD;
         15. Allergy to turmeric or any of its constituents, including curcumin, to yellow food&#xD;
             coloring, or to member of the Zingiberaceae (ginger) family&#xD;
&#xD;
         16. Gastric or duodenal ulcers, or gastric hyperacidity disorders&#xD;
&#xD;
         17. Hypersensitivity to any tetracyclines&#xD;
&#xD;
         18. Patients to be confirmed as not pregnant (serum HCG negative). The screening for this&#xD;
             will be done by the oncologist in qualifying for CXRT.&#xD;
&#xD;
         19. Patients with a history of cardiac disease, including angina and cardiac ischemia,&#xD;
             left ventricular hypertrophy, myocardial infarction, and mitral valve prolapse.&#xD;
&#xD;
         20. Patients taking antifungals, antiretrovirals, and macrolides that are strong CYP3A4&#xD;
             strong inhibitors including indinavir, nelfinavir, ritonavir, clarithromycin,&#xD;
             itraconazole, ketoconazole, and nefazodone.&#xD;
&#xD;
         21. Patients on anticoagulants (ie warfarin/heparin)&#xD;
&#xD;
         22. Patients with International Normalized Ratio (INR) &gt; 1.5.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongxing Liao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Concurrent Chemoradiation Therapy</keyword>
  <keyword>Side Effects</keyword>
  <keyword>Armodafinil</keyword>
  <keyword>Nuvigil</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Wellbutrin</keyword>
  <keyword>Wellbutrin SR</keyword>
  <keyword>Zyban</keyword>
  <keyword>Curcumin</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Dynacin</keyword>
  <keyword>Minocin</keyword>
  <keyword>Minocin PAC</keyword>
  <keyword>Myrac</keyword>
  <keyword>Solodyn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

